New Drugs and Clinical Trials · us
Exploring Intervention Before Symptoms Appear: Prion siRNA Trial Opens Enrollment to People at High Genetic Risk
The PRiSM trial is expanding to include carriers of high-risk genetic variants who have not yet developed disease, initially assessing the safety of a single dose and the extent of protein reduction. This is a step toward early intervention, but there is still a long way to go before proving it can delay disease onset.
For people carrying genetic variants associated with a high risk of prion disease, the years before symptoms appear are also an important period for exploring opportunities to intervene. On October 14, the PRiSM clinical trial, sponsored by the Broad Institute in the United States, announced that it was opening enrollment to this group to test an siRNA drug candidate intended to reduce the production of prion protein (PrP) in the brain. However, the study first seeks to establish safety and drug activity; it cannot yet determine whether the drug can prevent disease.
PRiSM began enrolling patients with symptoms earlier this year and has now added a presymptomatic cohort. According to a social media statement released by the research team, the trial is being conducted at five sites in the United States. Presymptomatic participants must be at least 18 years old, neurologically healthy, and have a predictive genetic test report confirming that they carry a PRNP variant associated with a high lifetime risk of developing disease. A family history alone does not meet this requirement.
The strategy targets the raw material from which the disease develops. When normal PrP misfolds, it can form disease-causing prions; researchers hope to explore the possibility of delaying disease by reducing the supply of PrP. The candidate, PrP-siRNA, was jointly developed by the Broad Institute and UMass Chan Medical School. It links two identical short interfering RNAs, a design intended to improve distribution in the brain, and reduces protein production by prompting cells to cleave the RNA needed to make PrP.
Allowing healthy people at high risk to receive the investigational drug requires a safety review at each dose level. Trial investigator Eric Vallabh Minikel explained that the presymptomatic cohort is currently starting at 50 milligrams because the data safety monitoring board considered the preliminary safety findings acceptable after a small number of symptomatic participants received this dose. Any higher doses must likewise first be tested in symptomatic patients. These data, involving small numbers of participants and short observation periods, remain insufficient to establish the drug’s safety.
This remains a single-dose Phase 1 trial. Participants receive an intrathecal injection through a lumbar puncture, stay overnight in the hospital for monitoring, and return for visits at weeks 1, 2, 4, 8, 12, and 24 after dosing. The study will track adverse events and measure PrP in cerebrospinal fluid to assess whether the drug has its intended effect. Some visits also include additional lumbar punctures, brain MRI scans, blood draws, and cognitive tests.
The study design also reflects differences between the two groups of participants. Prion Alliance said that the presymptomatic cohort has no separate observational group because the OBSERVE study at Massachusetts General Hospital has already accumulated observational data on this population. The Broad Institute stated that the National Institutes of Health’s NeuroNEXT program provides funding and the framework for conducting the trial, with clinical coordination handled by Massachusetts General Hospital and data and statistical support provided by the University of Iowa.
The key unknowns remain how much the drug can lower PrP in humans, how long that reduction lasts, and what risks accompany it. In this announcement, Minikel explicitly stated that the team does not yet have target engagement data showing PrP reduction and that the trial was not designed to demonstrate slower deterioration, longer survival, or delayed disease onset. Even if a single dose does lower PrP, that would not directly establish that lifetime disease risk has changed. The value of this step is to obtain initial human evidence to inform whether to proceed to larger trials and which doses and dosing frequency to use.